(+98)21-26413024

(+98)21-26411650

  • Home
  • weblog
  • FDA Approves Combivent Respimat Inhalation Spray

FDA Approves Combivent Respimat Inhalation Spray

Share
FDA Approves Combivent Respimat Inhalation Spray

Combivent Respimat is a suitable alternative for patients who are currently using Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol. Combivent Inhalation Aerosol is being phased out because it contains chlorofluorocarbons (CFCs). CFCs are chemical compounds that decrease the ozone layer. As a result, Combivent Inhalation Aerosol will not be available after December 31, 2013. Combivent Respimat does not contain CFCs.

Inhalers that contain CFCs are being phased out due to an international agreement called the Montreal Protocol on Substances that Deplete the Ozone Layer. By signing this agreement, the United States promised to make it illegal to make or sell substances that decrease the ozone layer. Most inhalers that contain CFCs have already been phased out as part of this agreement.

Patients who use Combivent Inhalation Aerosol will have another treatment option and a suitable alternative when Combivent Inhalation Aerosol is no longer available.

Comments

?Your opinion


captcha

FDA approves combination therapy Juvisync

The FDA has recently become aware of the potential for statins to increase ...

FDA Approves Combivent Respimat Inhalation Spray

Combivent Respimat is a suitable alternative for patients who are currently ...

FDA approves Interrmezzo for insomnia

This is the first time the FDA has approved a drug for this condition. ...

FDA approves first generic version of cholesterol-lowering drug Lipitor

The U.S. Food and Drug Administration today approved the first generic ...